BioCentury | Oct 24, 2013
Cover Story

A platform for RNA

...stable nucleic acid-lipid particles (SNALPs). The company gained the technology via its 2008 purchase of Protiva Biotherapeutics Inc....
BioCentury | Apr 6, 2009
Company News

Tekmira, Bristol-Myers deal

...undisclosed organs and tissues outside the liver using Tekmira's SNALP technology. Bristol-Myers first partnered with Protiva Biotherapeutics Inc....
...expanded in 2008 to include testing the delivery of siRNA to undisclosed organs. Tekmira acquired Protiva...
BioCentury | Aug 18, 2008
Company News

Tekmira, Bristol-Myers deal

...and tissues outside the liver using Tekmira’s SNALP technology. The original deal, between Bristol-Myers and Protiva Biotherapeutics Inc....
...the lipid nanoparticle delivery technology with the pharma’s siRNAs to validate gene targets. Tekmira acquired Protiva...
BioCentury | Jul 28, 2008
Clinical News

PLK1 SNALP: Phase I start

...will begin a Phase I trial. The company acquired PLK1 SNALP through its acquisition of Protiva Biotherapeutics Inc....
BioCentury | Jun 9, 2008
Company News

Protiva, Tekmira deal

...Tekmira completed its previously announced acquisition of Protiva for 22.8 million shares valued at C$31.5 million...
...May 30, the last day of trading before the deal closed (see BioCentury, April 7). Protiva Biotherapeutics Inc....
BioCentury | Apr 17, 2008
Targets & Mechanisms

shRNA: Solving the Subtle

...develop undisclosed siRNA drug delivery technologies. Like Silence, Protiva Biotherapeutics Inc. is using a lipid-based delivery vehicle. Protiva's...
...efficacy in nonhuman primates. 9 In addition to the delivery vehicle, CSO Ian MacLachlan said Protiva...
...Whitehouse Station, N.J. Opko Health Inc. (AMEX:OPK), Miami, Fla. Pfizer Inc. (NYSE:PFE), New York, N.Y. Protiva Biotherapeutics Inc....
BioCentury | Apr 7, 2008
Company News

Protiva, Tekmira, Alnylam, Roche deal

...Tekmira will acquire Protiva for 22.8 million shares valued at C$19.84 million (US$19.4 million) based on...
...before the deal was announced. Tekmira shareholders will own 48% of the combined company, and Protiva...
...$5 million at C$2.40 per share. The deal ended all outstanding litigation between Tekmira and Protiva...
BioCentury | Oct 22, 2007
Company News

Protiva, Merck deal

...therapeutics. Protiva will receive an undisclosed one-time payment and is eligible for milestones and royalties. Protiva...
...California Superior Court for the County of San Francisco in March (see BioCentury, April 23). Protiva Biotherapeutics Inc....
BioCentury | Apr 23, 2007
Company News

Protiva, Merck genomics news

...prohibiting MRK’s Sirna Therapeutics Inc. subsidiary from using, disclosing, transferring, licensing, selling or otherwise encumbering Protiva’s...
...siRNA" and may not use "any of the confidential and proprietary information it received from Protiva,"...
...is expected to begin by November. MRK acquired Sirna last December. MRK declined to comment. Protiva Biotherapeutics Inc....
BioCentury | Feb 12, 2007
Company News

Inex, Protiva drug delivery news

...The British Columbia Court of Appeals dismissed Protiva's appeal that sought to overturn a November 2006...
...to the technology to IEX spinout Tekmira Corp. without Protiva's consent (see BioCentury, Jan. 1). Protiva...
...claims that IEX holds no rights to the technology. IEX owns a minority stake in Protiva...
Items per page:
1 - 10 of 19
BioCentury | Oct 24, 2013
Cover Story

A platform for RNA

...stable nucleic acid-lipid particles (SNALPs). The company gained the technology via its 2008 purchase of Protiva Biotherapeutics Inc....
BioCentury | Apr 6, 2009
Company News

Tekmira, Bristol-Myers deal

...undisclosed organs and tissues outside the liver using Tekmira's SNALP technology. Bristol-Myers first partnered with Protiva Biotherapeutics Inc....
...expanded in 2008 to include testing the delivery of siRNA to undisclosed organs. Tekmira acquired Protiva...
BioCentury | Aug 18, 2008
Company News

Tekmira, Bristol-Myers deal

...and tissues outside the liver using Tekmira’s SNALP technology. The original deal, between Bristol-Myers and Protiva Biotherapeutics Inc....
...the lipid nanoparticle delivery technology with the pharma’s siRNAs to validate gene targets. Tekmira acquired Protiva...
BioCentury | Jul 28, 2008
Clinical News

PLK1 SNALP: Phase I start

...will begin a Phase I trial. The company acquired PLK1 SNALP through its acquisition of Protiva Biotherapeutics Inc....
BioCentury | Jun 9, 2008
Company News

Protiva, Tekmira deal

...Tekmira completed its previously announced acquisition of Protiva for 22.8 million shares valued at C$31.5 million...
...May 30, the last day of trading before the deal closed (see BioCentury, April 7). Protiva Biotherapeutics Inc....
BioCentury | Apr 17, 2008
Targets & Mechanisms

shRNA: Solving the Subtle

...develop undisclosed siRNA drug delivery technologies. Like Silence, Protiva Biotherapeutics Inc. is using a lipid-based delivery vehicle. Protiva's...
...efficacy in nonhuman primates. 9 In addition to the delivery vehicle, CSO Ian MacLachlan said Protiva...
...Whitehouse Station, N.J. Opko Health Inc. (AMEX:OPK), Miami, Fla. Pfizer Inc. (NYSE:PFE), New York, N.Y. Protiva Biotherapeutics Inc....
BioCentury | Apr 7, 2008
Company News

Protiva, Tekmira, Alnylam, Roche deal

...Tekmira will acquire Protiva for 22.8 million shares valued at C$19.84 million (US$19.4 million) based on...
...before the deal was announced. Tekmira shareholders will own 48% of the combined company, and Protiva...
...$5 million at C$2.40 per share. The deal ended all outstanding litigation between Tekmira and Protiva...
BioCentury | Oct 22, 2007
Company News

Protiva, Merck deal

...therapeutics. Protiva will receive an undisclosed one-time payment and is eligible for milestones and royalties. Protiva...
...California Superior Court for the County of San Francisco in March (see BioCentury, April 23). Protiva Biotherapeutics Inc....
BioCentury | Apr 23, 2007
Company News

Protiva, Merck genomics news

...prohibiting MRK’s Sirna Therapeutics Inc. subsidiary from using, disclosing, transferring, licensing, selling or otherwise encumbering Protiva’s...
...siRNA" and may not use "any of the confidential and proprietary information it received from Protiva,"...
...is expected to begin by November. MRK acquired Sirna last December. MRK declined to comment. Protiva Biotherapeutics Inc....
BioCentury | Feb 12, 2007
Company News

Inex, Protiva drug delivery news

...The British Columbia Court of Appeals dismissed Protiva's appeal that sought to overturn a November 2006...
...to the technology to IEX spinout Tekmira Corp. without Protiva's consent (see BioCentury, Jan. 1). Protiva...
...claims that IEX holds no rights to the technology. IEX owns a minority stake in Protiva...
Items per page:
1 - 10 of 19